1-7 of 7
Martine Van Glabbeke
Close
Sort by
Journal Articles

Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non- Hodgkin’s Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study

Marinus H.J. Van Oers, MD, PhD, Martine Van Glabbeke, Liliana Baila, MD, Livia Giurgia, Richard Klasa, Robert E Marcus, Max Wolf, Eva Kimby, Anton Hagenbeek
Journal: Blood
Blood (2008) 112 (11): 836.
https://doi.org/10.1182/blood.V112.11.836.836
Published: 2008
Journal Articles

Gem-(R)CHOP Versus (R)CHOP: A Randomized Phase II Study of Gemcitabine Combined with (R)CHOP in Untreated Aggressive Non- Hodgkin’s Lymphoma - EORTC Lymphoma Group Protocol 20021

Igor Aurer, Houchingue Eghbali, John M. Raemaekers, Hussein M Khaled, Martine Van Glabbeke, Liliana Baila, Richard van der Maazen
Journal: Blood
Blood (2008) 112 (11): 3609.
https://doi.org/10.1182/blood.V112.11.3609.3609
Published: 2008
Journal Articles

BCL-2/IgH PCR Values at the End of Induction Treatment Are Not Predictive for Progression Free Survival in Relapsed/Resistant Follicular Lymphoma: Results of a Prospective Randomized Phase III Intergroup Trial.

Bert A. van der Reijden, PhD, Marinus H.J Van Oers, MD.PhD, Evelyn Tonissen, Martine Van Glabbeke, PhD, Livia Giurgia, Richard Klasa, MD.PhD, Robert E. Marcus, MD.PhD, Max Wolf, MD.PhD, Mars Van t Veer, MD.PhD, Andrej Vranovsky, MD, Harald Holte, MD, Eva Kimby, MD, Anton Hagenbeek, MD.PhD
Journal: Blood
Blood (2007) 110 (11): 791.
https://doi.org/10.1182/blood.V110.11.791.791
Published: 2007
Journal Articles

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

Clinical Trials & Observations
Marinus H. J. van Oers, Richard Klasa, Robert E. Marcus, Max Wolf, Eva Kimby, Randy D. Gascoyne, Andrew Jack, Mars van't Veer, Andrej Vranovsky, Harald Holte, Martine van Glabbeke, Ivana Teodorovic, Cynthia Rozewicz, Anton Hagenbeek
Journal: Blood
Blood (2006) 108 (10): 3295–3301.
https://doi.org/10.1182/blood-2006-05-021113
Published: 2006
Journal Articles

Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma

Clinical Trials & Observations
Elizabeth C. Moser, Evert M. Noordijk, Flora E. van Leeuwen, Saskia le Cessie, Joke W. Baars, José Thomas, Patrice Carde, Jacobus H. Meerwaldt, Martine van Glabbeke, Hanneke C. Kluin-Nelemans
Journal: Blood
Blood (2006) 107 (7): 2912–2919.
https://doi.org/10.1182/blood-2005-08-3392
Published: 2006
Journal Articles

Chimeric Anti-CD20 Monoclonal Antibody (Rituximab;Mabthera) in Remission Induction and Maintenance Treatment of Relapsed /Resistant Follicular Non-Hodgkin’s Lymphoma: Final Analysis of a Phase III Randomized Intergroup Clinical Trial.

Marinus H.J. Van Oers, MD, PhD, Martine Van Glabbeke, PhD, Ivana Teodorovic, MD, Cynthia Rozewicz, Richard Klasa, MD, Robert E. Marcus, MD, Max Wolf, MD, Eva Kimby, MD, Anton Hagenbeek, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 353.
https://doi.org/10.1182/blood.V106.11.353.353
Published: 2005
Journal Articles

Chimeric Anti-CD20 Monoclonal Antibody (Rituximab; Mabtheraâ) in Remission Induction and Maintenance Treatment of Relapsed /Resistant Follicular Non-Hodgkin’s Lymphoma : A Phase III Randomized Intergroup Clinical Trial.

Marinus H.J. Van Oers, MD, PhD, Martine Van Glabbeke, Ivana Teodorovic, MD, Cynthia Rozewicz, Richard Klasa, MD, PhD, Robert E. Marcus, Max Wolf, MD, Eva Kimby, MD, Anton Hagenbeek, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 586.
https://doi.org/10.1182/blood.V104.11.586.586
Published: 2004